Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate

Abstract
To compare the clinical usefulness of the serum markers prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP), we measured them by radioim-munoassay in 2200 serum samples from 699 patients, 378 of whom had prostatic cancer.